98%
921
2 minutes
20
Introduction: Opioid use disorder is a U.S. epidemic, and recovery housing plays a critical role by providing stable, supportive environments that promote long-term recovery. However, little is known about the sustainability of recovery homes, particularly those serving people taking medications for opioid use disorder.
Methods: We applied thematic analysis to interviews with 29 staff and operators from 10 recovery homes serving people taking medications for opioid use disorder across five Texas cities.
Results: Operators relied on diverse funding sources, leveraged strategic partnerships and professional certifications, and planned to charge rent when public funding ended. Staff and operators balanced financial sustainability with maintaining quality services.
Discussion: Findings offer guidance for sustaining recovery homes that support medications for opioid use disorder. Recovery home operators can leverage professional networks, strengthen partnerships, rely on diverse funding sources, and reduce operational costs to sustain services. Policymakers can further support sustainability by establishing long-term funding mechanisms and reducing financial barriers to professional certification, ultimately improving service quality and access.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075534 | PMC |
http://dx.doi.org/10.3389/fpubh.2025.1528971 | DOI Listing |
Drug Saf
September 2025
School of Health Policy and Management, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada.
Introduction: At times it is necessary to withdraw drugs after they have been approved because of lack of effectiveness or safety concerns. Health Canada does not keep a list of withdrawn drugs.
Objective: The aim of this study was to generate a list of all drugs approved since 1990 and subsequently withdrawn from the Canadian market for safety or effectiveness reasons until the end of 2024.
J Safety Res
September 2025
Department of Emergency Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada. Electronic address:
Introduction: Older adults are increasingly involved in motor vehicle collisions (MVCs). Hypnotics are known to impair driving ability. This study investigated the prevalence of hypnotics use among older adult drivers involved in MVCs and evaluated their impact on injury severity and co-prevalence with other central nervous system (CNS) depressants.
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. Electronic address:
Ethnopharmacological Relevance: Chronic inflammatory pain represents a significant global health burden, seriously affecting the patient's quality of life. Jin-Tian-Ge Capsules (JTG), a substitute for natural tiger bone, has been approved in China for the treatment of osteoporosis, osteoarthritis and rheumatoid arthritis. Clinical observations show that JTG can mitigate chronic pain associated with the above bone-related diseases.
View Article and Find Full Text PDFN Engl J Med
September 2025
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst.
Background: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
Methods: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.
A A Pract
September 2025
Department of Anesthesiology, Ospedale San Giovanni, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Childbirth-Related Posttraumatic Stress Disorder (CB-PTSD) can arise even after low-risk deliveries. This case report describes a 35-year-old woman who, despite a medically uncomplicated vaginal birth, developed severe CB-PTSD after being denied neuraxial analgesia and receiving remifentanil-PCA (remi-PCA) to manage pain. Her distress stemmed from inadequate pain relief, dissociation, and loss of control, exacerbated by unmet expectations for epidural analgesia.
View Article and Find Full Text PDF